Literature DB >> 7940136

Longterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma.

J Collignon-Brach1.   

Abstract

In a prospective, randomized study, nineteen patients with ocular hypertension (n = 14) or chronic open-angle glaucoma (n = 5) were treated with either betaxolol 0.5% or timolol 0.5% in both eyes twice daily. Visual field sensitivity and intraocular pressure were assessed with the Octopus perimeter (program G1) and applanation tonometry, respectively, at 3, 6, 12, 24, 36, and 48 months during treatment. Four of the nineteen patients (two timolol-treated and two betaxolol-treated) were lost to follow-up after the 36-month examination. Whereas both drugs reduced the intraocular pressure, the decrease in the timolol-treated group was statistically more pronounced than in the betaxolol-treated group at month 3, 6, and 48 (p < 0.03). In both treatment groups, the visual field mean sensitivity (MS) index decreased slightly during the first six months of treatment, but remained so only in the timolol-treated group at all subsequent examinations. In the betaxolol-treated group, there was a statistically significant increase in MS at the 12, 24, 36, and 48 month visits (p < 0.01). These findings suggest that factors other than IOP alone may determine visual field outcome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7940136     DOI: 10.1016/0039-6257(94)90059-0

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  13 in total

1.  The effect of topical glaucoma medications evaluated by perimetry.

Authors:  J-C Lin; F Samuel; L J Katz; G L Spaeth; J Hoop; L B Cantor
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

Review 2.  Normal tension glaucoma--a practical approach.

Authors:  D Kamal; R Hitchings
Journal:  Br J Ophthalmol       Date:  1998-07       Impact factor: 4.638

3.  Topically administered timolol and dorzolamide reduce intraocular pressure and protect retinal ganglion cells in a rat experimental glaucoma model.

Authors:  M Seki; T Tanaka; H Matsuda; T Togano; K Hashimoto; J Ueda; T Fukuchi; H Abe
Journal:  Br J Ophthalmol       Date:  2005-04       Impact factor: 4.638

4.  Acquired color vision loss and a possible mechanism of ganglion cell death in glaucoma.

Authors:  T M Nork
Journal:  Trans Am Ophthalmol Soc       Date:  2000

5.  Effect and mechanism of betaxolol and timolol on vascular relaxation in isolated rabbit ciliary artery.

Authors:  Yaru Dong; Hitoshi Ishikawa; Yazhen Wu; Kimiya Shimizu; Toshiaki Goseki; Takeshi Yoshitomi
Journal:  Jpn J Ophthalmol       Date:  2006-12-18       Impact factor: 2.447

Review 6.  Pharmacological neuroprotection for glaucoma.

Authors:  Glyn Chidlow; John P M Wood; Robert J Casson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists.

Authors:  G Chidlow; J Melena; N N Osborne
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

8.  Results of the betaxolol versus placebo treatment trial in ocular hypertension.

Authors:  Deborah Kamal; David Garway-Heath; Simon Ruben; Fiona O'Sullivan; Catey Bunce; Anath Viswanathan; Wendy Franks; Roger Hitchings
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-02-19       Impact factor: 3.117

9.  Effects of betaxolol and flunarizine on visual fields and intraocular pressure in patients with migraine.

Authors:  Alper Yarangümeli; Selçuk Comoglu; Ozlem Gürbüz Köz; Atilla Halil Elhan; Gülcan Kural
Journal:  Doc Ophthalmol       Date:  2003-05       Impact factor: 2.379

Review 10.  Medical interventions for primary open angle glaucoma and ocular hypertension.

Authors:  C Vass; C Hirn; T Sycha; O Findl; P Bauer; L Schmetterer
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.